Literature DB >> 10160071

Cost-effectiveness guidelines. The experience of Australian manufacturers.

P Gorham1.   

Abstract

Mesh:

Year:  1995        PMID: 10160071     DOI: 10.2165/00019053-199508050-00001

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN: 1170-7690            Impact factor:   4.981


× No keyword cloud information.
  6 in total

1.  Basing prescription drug payment on economic analysis: the case of Australia.

Authors:  M F Drummond
Journal:  Health Aff (Millwood)       Date:  1992       Impact factor: 6.301

2.  Australian guidelines for cost-effectiveness studies of pharmaceuticals: the thin end of the boomerang?

Authors:  M Drummond
Journal:  Pharmacoeconomics       Date:  1992       Impact factor: 4.981

3.  Economic analysis as an aid to subsidisation decisions: the development of Australian guidelines for pharmaceuticals.

Authors:  D Henry
Journal:  Pharmacoeconomics       Date:  1992-01       Impact factor: 4.981

4.  'This house believes that pharmacoeconomic analysis should be mandated by governments rather than left to market forces'.

Authors:  J M Eisenberg; D B Evans; T Walley; B Lovatt
Journal:  Pharmacoeconomics       Date:  1994-10       Impact factor: 4.981

5.  The emerging government requirement for economic evaluation of pharmaceuticals.

Authors:  M Drummond
Journal:  Pharmacoeconomics       Date:  1994       Impact factor: 4.981

6.  Choosing from the health care reform menu.

Authors:  H J Aaron
Journal:  J Am Health Policy       Date:  1991 Nov-Dec
  6 in total
  3 in total

1.  Using economic evaluations to make formulary coverage decisions. So much for guidelines.

Authors:  A H Anis; Y Gagnon
Journal:  Pharmacoeconomics       Date:  2000-07       Impact factor: 4.981

Review 2.  Low-Dose Azathioprine in Combination with Allopurinol: The Past, Present and Future of This Useful Duo.

Authors:  Alexander Keith Turbayne; Miles Patrick Sparrow
Journal:  Dig Dis Sci       Date:  2022-10-15       Impact factor: 3.487

Review 3.  Cost of pharmacological care of the elderly: implications for healthcare resources.

Authors:  Ciaran O'Neill; Carmel M Hughes; James Jamison; Anna Schweizer
Journal:  Drugs Aging       Date:  2003       Impact factor: 3.923

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.